North Immunology is a privately held biotechnology company developing bispecific antibodies that target orthogonal inflammatory pathways in immune and inflammatory diseases. Its lead program, NOR-101, is a half-life-extended IL-13 x IL-18 bispecific antibody in development for atopic dermatitis. The company is going public through a reverse merger with Aethlon Medical.
Reverse merger with Aethlon Medical (expected to trade on Nasdaq as NRTX after closing in Q1 2027)
Expected start of the Phase 1a study of NOR-101
Interim pharmacokinetic and safety data from the NOR-101 Phase 1a study
Expected closing of the Aethlon Medical reverse merger
North Immunology is going public through an all-stock reverse merger with Aethlon Medical, paired with an oversubscribed $180 million private placement that is expected to fund its eczema drug program into the second half of 2028.
North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug
Chief Executive Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Chairman of the Board